학술논문
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
Document Type
Article
Author
Ritchlin, Christopher T.; Helliwell, Philip S.; Boehncke, Wolf-Henning; Soriano, Enrique R.; Hsia, Elizabeth C.; Kollmeier, Alexa P.; Chakravarty, Soumya D.; Zazzetti, Federico; Subramanian, Ramanand A.; Xu, Xie L.; Zuraw, Qing C.; Shihong Sheng; Yusang Jiang; Agarwal, Prasheen; Bei Zhou; Yanli Zhuang; Shawi, May; Karyekar, Chetan S.; Deodhar, Atul
Source
RMD Open; 2/15/2021, Vol. 7 Issue 1, p1-11, 11p
Subject
Language
ISSN
20565933